Geron mit Hammernews!! (Seite 57)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 10.06.24 22:20:11 von
neuester Beitrag 10.06.24 22:20:11 von
Beiträge: 3.096
ID: 709.348
ID: 709.348
Aufrufe heute: 17
Gesamt: 213.723
Gesamt: 213.723
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GON
4,5630
EUR
+0,31 %
+0,0140 EUR
Letzter Kurs 14.06.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
07.06.24 · wO Chartvergleich |
07.06.24 · dpa-AFX |
07.06.24 · Business Wire (engl.)  |
16.05.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +2.566,67 | |
| 3,3000 | +44,74 | |
| 1,2200 | +31,76 | |
| 1,2450 | +29,69 | |
| 7,7600 | +29,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7900 | -24,80 | |
| 1,0100 | -26,81 | |
| 9,5300 | -34,00 | |
| 1,0200 | -34,19 | |
| 1,2400 | -34,39 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 57.186.842 von bernie55 am 05.03.18 10:51:03
AFTER TRADING HOURS : WHAT`S GOING ON ????
Zitat von bernie55: Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial Results[/b]
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close . Geron’s management will also host a conference call for analysts and investors on Monday, March 19, 2018, at 8:30 a.m. Eastern Time > um 14.30 Uhr MEZ to discuss the company’s fourth quarter and annual results as well as recent events.
A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at https://edge.media-server.com/m6/p/4hrpsmd2.
AFTER TRADING HOURS : WHAT`S GOING ON ????
Antwort auf Beitrag Nr.: 57.304.411 von bernie55 am 16.03.18 23:51:33.....somit keine negative Überraschung bzgl. des Finanzberichtes - 4Q 2017....
Antwort auf Beitrag Nr.: 57.186.842 von bernie55 am 05.03.18 10:51:03Geron reports 4Q loss
......was zu erwarten war...
Associated Press•March 16, 2018
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Friday reported a loss of $7.4 million in its fourth quarter.
On a per-share basis, the Menlo Park, California-based company said it had a loss of 5 cents....
......was von Analysten prognostiziert wurde....
The drugmaker posted revenue of $191,000 in the period.
For the year, the company reported that its loss narrowed to $27.9 million, or 18 cents per share. Revenue was reported as $1.1 million.
https://finance.yahoo.com/news/geron-reports-4q-loss-2025236…
......was zu erwarten war...
Associated Press•March 16, 2018
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Friday reported a loss of $7.4 million in its fourth quarter.
On a per-share basis, the Menlo Park, California-based company said it had a loss of 5 cents....
......was von Analysten prognostiziert wurde....
The drugmaker posted revenue of $191,000 in the period.
For the year, the company reported that its loss narrowed to $27.9 million, or 18 cents per share. Revenue was reported as $1.1 million.
https://finance.yahoo.com/news/geron-reports-4q-loss-2025236…
Antwort auf Beitrag Nr.: 57.186.842 von bernie55 am 05.03.18 10:51:03
..........es wird spannend........
A Few Key Words At Geron's Upcoming Conference Call Could Light Up The Stock
Mar.14.18
Summary
- Investors will be looking for an update on the iMbark trial at next Monday's quarterly conference call
- As median survival estimates grow, so do sales estimates of lead drug Imetelstat.
- Valuation may break $1 billion on good news.
Investors will be looking for an update on the iMbark trial at next Monday's quarterly conference call
https://seekingalpha.com/article/4156431-key-words-gerons-up…
Zitat von bernie55: Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial Results
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close. Geron’s management will also host a conference call for analysts and investors on Monday, March 19, 2018, at 8:30 a.m. Eastern Time to discuss the company’s fourth quarter and annual results as well as recent events.
https://finance.yahoo.com/news/geron-announces-conference-ca…
..........es wird spannend........
A Few Key Words At Geron's Upcoming Conference Call Could Light Up The Stock
Mar.14.18
Summary
- Investors will be looking for an update on the iMbark trial at next Monday's quarterly conference call
- As median survival estimates grow, so do sales estimates of lead drug Imetelstat.
- Valuation may break $1 billion on good news.
Investors will be looking for an update on the iMbark trial at next Monday's quarterly conference call
https://seekingalpha.com/article/4156431-key-words-gerons-up…
Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial Results
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close. Geron’s management will also host a conference call for analysts and investors on Monday, March 19, 2018, at 8:30 a.m. Eastern Time to discuss the company’s fourth quarter and annual results as well as recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 3564078. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at https://edge.media-server.com/m6/p/4hrpsmd2.
The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 20, 2018.
https://finance.yahoo.com/news/geron-announces-conference-ca…
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close. Geron’s management will also host a conference call for analysts and investors on Monday, March 19, 2018, at 8:30 a.m. Eastern Time to discuss the company’s fourth quarter and annual results as well as recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 3564078. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at https://edge.media-server.com/m6/p/4hrpsmd2.
The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 20, 2018.
https://finance.yahoo.com/news/geron-announces-conference-ca…
Trading Spotlight
Antwort auf Beitrag Nr.: 56.876.237 von bernie55 am 30.01.18 17:16:23
..eine mögliche Erklärung für das UP ! ?...
Why Geron Corporation Stock Ripped Higher in January
George Budwell,
The Motley Fool•February 4, 2018
What happened
Shares of clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by a noteworthy 36.1% in January, according to S&P Global Market Intelligence . What drove this breakout?
In late January, Geron's development partner, Johnson & Johnson (NYSE: JNJ), listed the company's anti-cancer drug, imetelstat, as a top experimental compound during its latest clinical pipeline update. This update, in turn, appears to have sparked a classic short squeeze in Geron's stock.
So what
Geron's stock has been a favorite target of short-sellers for most of the past year. One of the major reasons is a so-called "information request" from the U.S. Food and Drug Administration (FDA) pertaining to imetelstat's risk-to-reward ratio in advanced myelofibrosis patients. This unexpected information request was disclosed last October, which was accompanied by a stunning 18.2% rise in Geron's short interest over the past two and a half months.
The reason? Short-sellers were apparently betting that this regulatory development would turn out to be a prelude to a clinical hold, or an outright cessation, of imetelstat's ongoing myelofibrosis trial. Either of these regulatory setbacks would probably spell the end of J&J's involvement in imetelstat's clinical development, and perhaps even the end of Geron. This biotech, after all, has no other clinical assets outside of imetelstat, and nowhere near enough cash to reconstitute its pipeline from scratch.
Now what
With a clinical hold or a suspension seemingly off the table, imetelstat appears to be cleared to reach its next internal data review, scheduled to occur before the end of this quarter. And if history is any guide, J&J and Geron should unveil this all-important clinical update around April 1.
What should investors expect? The big ticket item is imetelstat's maturing overall survival data in advanced myelofibrosis. Although it's impossible to quantitatively handicap the trial's ultimate outcome for this key efficacy measure, the trend, so far, is extremely encouraging.
The median overall survival for relapsed/refractory myleofibrosis patients, after all, is only 14 months, according to the most optimistic of estimates. Patient dosing in imetelstat's myelofibrosis trial, however, closed about 16 months ago -- yet median overall survival still hasn't been reached. As the bulk of patients were actually enrolled over 16 months ago, it certainly looks as if imetelstat is bending the curve on overall survival in these sickly patients who currently have no real treatment options. If true, imetelstat has a real shot at living up to its billion dollar-plus peak sales estimates for its first indication -- meaning that short-sellers may want to steer clear of this all-or-nothing stock right now.
https://finance.yahoo.com/news/why-geron-corporation-stock-r…
Zitat von bernie55: Was ist das denn heute für ein UP-Move und dann noch mit diesem Extrem-Volumen ???
Dass dieser allein mit dem Artikel von Seeking Alpha zu tun hat, kann ich irgendwie nicht glauben.
Sind schon erste Infos zu den Trials durchgesickert ?
Buyout in Vorbereitung ?
..eine mögliche Erklärung für das UP ! ?...
Why Geron Corporation Stock Ripped Higher in January
George Budwell,
The Motley Fool•February 4, 2018
What happened
Shares of clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by a noteworthy 36.1% in January, according to S&P Global Market Intelligence . What drove this breakout?
In late January, Geron's development partner, Johnson & Johnson (NYSE: JNJ), listed the company's anti-cancer drug, imetelstat, as a top experimental compound during its latest clinical pipeline update. This update, in turn, appears to have sparked a classic short squeeze in Geron's stock.
So what
Geron's stock has been a favorite target of short-sellers for most of the past year. One of the major reasons is a so-called "information request" from the U.S. Food and Drug Administration (FDA) pertaining to imetelstat's risk-to-reward ratio in advanced myelofibrosis patients. This unexpected information request was disclosed last October, which was accompanied by a stunning 18.2% rise in Geron's short interest over the past two and a half months.
The reason? Short-sellers were apparently betting that this regulatory development would turn out to be a prelude to a clinical hold, or an outright cessation, of imetelstat's ongoing myelofibrosis trial. Either of these regulatory setbacks would probably spell the end of J&J's involvement in imetelstat's clinical development, and perhaps even the end of Geron. This biotech, after all, has no other clinical assets outside of imetelstat, and nowhere near enough cash to reconstitute its pipeline from scratch.
Now what
With a clinical hold or a suspension seemingly off the table, imetelstat appears to be cleared to reach its next internal data review, scheduled to occur before the end of this quarter. And if history is any guide, J&J and Geron should unveil this all-important clinical update around April 1.
What should investors expect? The big ticket item is imetelstat's maturing overall survival data in advanced myelofibrosis. Although it's impossible to quantitatively handicap the trial's ultimate outcome for this key efficacy measure, the trend, so far, is extremely encouraging.
The median overall survival for relapsed/refractory myleofibrosis patients, after all, is only 14 months, according to the most optimistic of estimates. Patient dosing in imetelstat's myelofibrosis trial, however, closed about 16 months ago -- yet median overall survival still hasn't been reached. As the bulk of patients were actually enrolled over 16 months ago, it certainly looks as if imetelstat is bending the curve on overall survival in these sickly patients who currently have no real treatment options. If true, imetelstat has a real shot at living up to its billion dollar-plus peak sales estimates for its first indication -- meaning that short-sellers may want to steer clear of this all-or-nothing stock right now.
https://finance.yahoo.com/news/why-geron-corporation-stock-r…
Antwort auf Beitrag Nr.: 56.876.237 von bernie55 am 30.01.18 17:16:23
GERON: January 30 - 4:00PM EST
2.53 USD : +0.18 (+7.66%)
Volume 13,764,527
Avg. Volume 1,960,835
Zitat von bernie55: Was ist das denn heute für ein UP-Move und dann noch mit diesem Extrem-Volumen ???
Dass dieser allein mit dem Artikel von Seeking Alpha zu tun hat, kann ich irgendwie nicht glauben.
Sind schon erste Infos zu den Trials durchgesickert ?
Buyout in Vorbereitung ?
GERON: January 30 - 4:00PM EST
2.53 USD : +0.18 (+7.66%)
Volume 13,764,527
Avg. Volume 1,960,835
Antwort auf Beitrag Nr.: 56.876.237 von bernie55 am 30.01.18 17:16:23wir haben ja im letzten Jahr bei den extremen Abschwüngen gesehen das Insider 2 Tage vor Bekanntgabe der Nachrichten verkauft haben. Jetzt ist es umgekehrt.Ich rechne in den nächsten Tagen mit einer positiven Meldung....was auch immer.
Antwort auf Beitrag Nr.: 56.872.523 von bernie55 am 30.01.18 12:21:45Was ist das denn heute für ein UP-Move und dann noch mit diesem Extrem-Volumen ???
Dass dieser allein mit dem Artikel von Seeking Alpha zu tun hat, kann ich irgendwie nicht glauben.
Sind schon erste Infos zu den Trials durchgesickert ?
Buyout in Vorbereitung ?
Dass dieser allein mit dem Artikel von Seeking Alpha zu tun hat, kann ich irgendwie nicht glauben.
Sind schon erste Infos zu den Trials durchgesickert ?
Buyout in Vorbereitung ?
Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte
Jan.29.18
Summary
- Celgene's profitability would be wiped out if Revlimid sales stumble.
- Geron's impending dominance in Myelofibrosis makes Celgene's $7B acquisition of Impact Biomedicines a tragic bungle.
- Geron may be the real nightmare Celgene's investors fear and may soon become reality as Imetelstat shows superior results compared to Revlimid in Myelodysplastic Syndrome patients.
https://seekingalpha.com/article/4140915-little-geron-may-so…[/quote]
Jan.29.18
Summary
- Celgene's profitability would be wiped out if Revlimid sales stumble.
- Geron's impending dominance in Myelofibrosis makes Celgene's $7B acquisition of Impact Biomedicines a tragic bungle.
- Geron may be the real nightmare Celgene's investors fear and may soon become reality as Imetelstat shows superior results compared to Revlimid in Myelodysplastic Syndrome patients.
https://seekingalpha.com/article/4140915-little-geron-may-so…[/quote]
Durchsuchen
Geron mit Hammernews!!
